A Centre-Randomized, Open-Label, Cross-Over Study to Compare the Pharmaco-Economic Consequences of an Ultiva (Remifentanil Hydrochloride) Based Regimen With Conventional Sedative Based Regimens in ICU Subjects Requiring Short-Term Mechanical Ventilation With Analgesia and Sedation

NCT00158873 Phase 4 COMPLETED

The study will evaluate the pharmaco-economic consequences of the use of a remifentanil based regimen compared with a conventional sedative based regimen in terms of duration of mechanical ventilation, length of stay in ICU, difference in extubation time and use of concomitant sedative agents.

Details

Lead sponsor	GlaxoSmithKline
Phase	Phase 4
Status	COMPLETED
Enrolment	224
Start date	2004-09

Conditions

• Sedation

Interventions

• midazolam
• lorazepam
• fentanyl
• morphine
• remifentanil
• propofol

Primary outcomes

• Health Outcome: Duration of time on mechanical ventilation

Countries

Netherlands